Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin IP vs IV for Peritonitis Prevention in PD
NCT03046511Phase 3Unknown
- Sponsor
- Carmel Medical Center
- Start
- Mar 2017
- Primary completion
- Dec 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefazolin in peritonitis (2 arms), sponsored by Carmel Medical Center. Primary endpoint: Peritonitis at 14 days. Status: unknown.
02
Drugs
cefazolin
03
Conditions
peritonitis
Beyond the preview
Go deeper on NCT03046511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046511.